Sigyn Therapeutics is advancing CardioDialysis, a medical device designed to treat cardiovascular disease through blood purification, with potential advantages over existing therapies and a strategic approach leveraging existing dialysis infrastructure. Cardiovascular disease remains the leading cause of death worldwide, and current treatments face significant limitations in both efficacy and accessibility.
While LDL-C reducing statins, the leading class of cardiovascular drugs, are associated with 25% reductions in Major Adverse Cardiovascular Events (MACE), blood purification through lipoprotein apheresis has demonstrated 75% to 95% reductions in MACE according to American Heart Association research published at https://www.ahajournals.org/doi/10.1161/ATV.0000000000000177. However, lipoprotein apheresis treatments are limited to approximately 60 specialized centers in the United States due to delivery infrastructure constraints.
CardioDialysis addresses this accessibility barrier by being deployable on dialysis machines already located at more than 7,500 kidney dialysis clinics across the country. This represents a significant expansion potential for blood purification treatments, as lipoprotein apheresis devices cannot operate on standard dialysis equipment. The device has demonstrated broad-spectrum clearance capabilities in vitro, addressing twelve therapeutic targets below 200nm in diameter, including inflammatory molecules not targeted by current market-approved therapies.
The clinical importance of this development is particularly significant for end-stage renal disease patients, who face disproportionately high cardiovascular disease rates. According to the U.S. Renal Data System, cardiovascular disease accounts for 67% of ESRD patient deaths, with incidence up to 20 times higher than in the general population. Drugs to treat cardiovascular disease have not reduced cardiovascular events in dialysis patients, and circulating levels of lipoprotein(a), which lacks an approved drug treatment, are 2-4 times higher in this population.
Sigyn's clinical strategy represents another innovative aspect of their approach. Rather than conducting studies in hospital intensive care units, which presents enrollment challenges for life-threatening conditions, the company plans to enroll ESRD patients at their regular dialysis clinics. CardioDialysis would be administered during scheduled dialysis treatments, potentially reducing both the time and cost required for clinical studies. This strategy applies to both human feasibility safety studies and pivotal efficacy studies required for market approval consideration.
The potential impact extends beyond patient outcomes to the dialysis industry itself. With cardiovascular disease as the leading cause of ESRD deaths, reducing MACE could extend patient lives. Based on average annual per-patient revenues of $65,000, dialysis industry revenues could increase by $2.8 billion for each month that U.S. dialysis patient lives are extended. Furthermore, CardioDialysis introduces a pathway for dialysis clinics to treat cardiovascular disease in the general population, potentially transforming current kidney dialysis clinics into future renal and cardiovascular treatment centers.
Research supporting the efficacy of current cardiovascular treatments, including statin limitations, has been documented in publications such as https://pmc.ncbi.nlm.nih.gov/articles/PMC12359277/. CardioDialysis has demonstrated safety and tolerability in porcine animal studies conducted at the University of Michigan, providing preliminary evidence for its potential clinical application. The device represents a substantial initial market opportunity, given that approximately 550,000 ESRD patients receive about 85 million dialysis treatments annually in the United States alone.
